CANNABICS®
RCC-33

The world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer based on our novel and proprietary formulation Cannabics® RCC-33

CANNABICS PHARMACEUTICALS

Proud to be a global leader in the development
of cancer & cancer related cannabinoid-molecule based therapeutic
formulations and medicines

PIONEER IN CANNABINOID-BASED ANTITUMOR RESEARCH

Cannabics Pharmaceuticals has been
conducting research on the antitumor effects of
cannabinoid formulations on cancer since its
establishment in 2012.

 Yellow marker: dead cancer cells after 24 hrs.

Drug Discovery
Platform

Cannabics Pharmaceuticals’ groundbreaking research and development is carried out in our in-house state of the art drug discovery facilities using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics.

DRUG CANDIDATES